PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
Author Information
Author(s): Dorina Veliceasa, Frank Thilo Schulze-Hoëpfner, Olga V. Volpert
Primary Institution: Feinberg School of Medicine, Northwestern University
Hypothesis
PPARγ is a potential modulator of angiogenesis and an important target for therapies against cancer.
Conclusion
PPARγ agonists can have both anti-angiogenic and pro-angiogenic effects, complicating their use in cancer treatment.
Supporting Evidence
- PPARγ has pleiotropic effects on survival and proliferation of multiple cell types, including cancer cells.
- Some studies identify pro-angiogenic and tumor-promoting effects of PPARγ and its ligands.
- Natural and synthetic PPARγ ligands block VEGF-driven angiogenesis in vivo.
- PPARγ ligands can enhance the expression of endothelial markers in circulating endothelial progenitor cells.
Takeaway
PPARγ is a protein that can help fight cancer, but it can also sometimes help tumors grow, so scientists are trying to find the best ways to use it safely.
Methodology
The article reviews existing studies on PPARγ and its ligands, discussing their effects on cancer and angiogenesis.
Limitations
The complexity of PPARγ's dual role in promoting and inhibiting tumor growth requires further research to clarify its mechanisms.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website